Ethics of clinical trials from bayesian perspective: Randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7404.1456 (Published 26 June 2003) Cite this as: BMJ 2003;326:1456
  1. Freddie C Hamdy (F.C.Hamdy@sheffield.ac.uk), professor of urology,
  2. Jenny L Donovan, professor of social medicine,
  3. J Athene Lane, research fellow,
  4. David E Neal, professor of surgical oncology
  1. Academic Urology Unit, Royal Hallamshire Hospital, Sheffield S10 2JF
  2. Department of Social Medicine, University of Bristol, Bristol BS8 2PR
  3. Oncology Centre, Addenbrooke's Hospital, Box 193, Cambridge CB2 2QQ FCH, JLD, and DEN are principal investigators and JAL is coordinator of the ProtecT study.

    EDITOR—Lilford uses the example of the ProtecT study to raise concerns about recruitment to clinical trials, taking quotations out of context from Donovan et al.1 2 Lilford asserts that in this study men are simply told that the best treatment for localised prostate cancer is “uncertain” that they are not given enough information or time to question the recruiter about essential details about treatments and side effects; and that …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription